Rosenberg Matthew Hamilton Sells 849 Shares of GSK plc (NYSE:GSK)

Rosenberg Matthew Hamilton lessened its holdings in GSK plc (NYSE:GSK) by 32.0% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,801 shares of the pharmaceutical company’s stock after selling 849 shares during the period. Rosenberg Matthew Hamilton’s holdings in GSK were worth $61,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Eastern Bank bought a new position in GSK in the third quarter worth approximately $26,000. ST Germain D J Co. Inc. raised its holdings in GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 522 shares during the period. Sunbelt Securities Inc. raised its holdings in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares during the period. Concord Wealth Partners lifted its position in GSK by 231.8% during the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after purchasing an additional 547 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC bought a new stake in GSK during the second quarter valued at about $37,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on GSK. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Finally, Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Trading Down 1.8 %

GSK stock opened at $32.12 on Wednesday. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The firm’s 50 day moving average price is $34.20 and its 200-day moving average price is $38.08. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.92. The stock has a market cap of $66.57 billion, a P/E ratio of 20.86, a PEG ratio of 1.52 and a beta of 0.63.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, January 9th. Shareholders of record on Friday, November 15th were paid a $0.3928 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.57 annualized dividend and a yield of 4.89%. This is a boost from GSK’s previous quarterly dividend of $0.38. GSK’s payout ratio is presently 95.45%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.